147 related articles for article (PubMed ID: 36933202)
21. Access disparities and underutilization of germline genetic testing in Chilean breast cancer patients.
Acevedo F; Walbaum B; Camus M; Manzor M; Muñiz S; Medina L; Petric M; Reyes P; Domínguez F; Puschel K; Merino T; Bravo ML; Pinto MP; Ibáñez C; Hughes K; Sánchez C
Breast Cancer Res Treat; 2023 Jun; 199(2):363-370. PubMed ID: 36988750
[TBL] [Abstract][Full Text] [Related]
22. Pancreatic cancer screening in high-risk individuals with germline genetic mutations.
DaVee T; Coronel E; Papafragkakis C; Thaiudom S; Lanke G; Chakinala RC; Nogueras González GM; Bhutani MS; Ross WA; Weston BR; Lee JH
Gastrointest Endosc; 2018 Jun; 87(6):1443-1450. PubMed ID: 29309780
[TBL] [Abstract][Full Text] [Related]
23. BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer.
Nilsson MP; Törngren T; Henriksson K; Kristoffersson U; Kvist A; Silfverberg B; Borg Å; Loman N
Breast Cancer Res Treat; 2018 Feb; 168(1):117-126. PubMed ID: 29164420
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the need for routine clinical testing of PALB2 c.1592delT mutation in BRCA negative Northern Finnish breast cancer families.
Haanpää M; Pylkäs K; Moilanen JS; Winqvist R
BMC Med Genet; 2013 Aug; 14():82. PubMed ID: 23941127
[TBL] [Abstract][Full Text] [Related]
25. Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in
Saldia A; Olson SH; Nunes P; Liang X; Samson ML; Salo-Mullen E; Marcell V; Stadler ZK; Allen PJ; Offit K; Kurtz RC
Cancer Prev Res (Phila); 2019 Sep; 12(9):599-608. PubMed ID: 31337648
[TBL] [Abstract][Full Text] [Related]
26. Development of a high risk pancreatic screening clinic using 3.0 T MRI.
Barnes CA; Krzywda E; Lahiff S; McDowell D; Christians KK; Knechtges P; Tolat P; Hohenwalter M; Dua K; Khan AH; Evans DB; Geurts J; Tsai S
Fam Cancer; 2018 Jan; 17(1):101-111. PubMed ID: 29101607
[TBL] [Abstract][Full Text] [Related]
27. Germline molecular data in hereditary breast cancer in Brazil: Lessons from a large single-center analysis.
Sandoval RL; Leite ACR; Barbalho DM; Assad DX; Barroso R; Polidorio N; Dos Anjos CH; de Miranda AD; Ferreira ACSM; Fernandes GDS; Achatz MI
PLoS One; 2021; 16(2):e0247363. PubMed ID: 33606809
[TBL] [Abstract][Full Text] [Related]
28. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
[TBL] [Abstract][Full Text] [Related]
29. Validation of a next generation sequencing assay for BRCA1, BRCA2, CHEK2 and PALB2 genetic testing.
Sim WC; Lee CY; Richards R; Bettens K; Mottier V; Goh LL
Exp Mol Pathol; 2020 Oct; 116():104483. PubMed ID: 32531196
[TBL] [Abstract][Full Text] [Related]
30. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
[TBL] [Abstract][Full Text] [Related]
31. The implications of BRCA loss of heterozygosity (LOH) and deficient mismatch repair gene (dMMR) expression in the breast cancer of a patient with both inherited breast and ovarian cancer syndrome (BRCA2) and Lynch syndrome (MLH1).
Sorscher S; Ansley K; Delaney SD; Ramkissoon S
Breast Cancer Res Treat; 2020 Apr; 180(2):511-514. PubMed ID: 32040686
[TBL] [Abstract][Full Text] [Related]
32. Germline Genetic Mutations in a Multi-center Contemporary Cohort of 550 Phyllodes Tumors: An Opportunity for Expanded Multi-gene Panel Testing.
Rosenberger LH; Thomas SM; Nimbkar SN; Hieken TJ; Ludwig KK; Jacobs LK; Miller ME; Gallagher KK; Wong J; Neuman HB; Tseng J; Hassinger TE; Jakub JW
Ann Surg Oncol; 2020 Oct; 27(10):3633-3640. PubMed ID: 32504368
[TBL] [Abstract][Full Text] [Related]
33. BRCA2 and pancreatic cancer.
Naderi A; Couch FJ
Int J Gastrointest Cancer; 2002; 31(1-3):99-106. PubMed ID: 12622420
[TBL] [Abstract][Full Text] [Related]
34. Assessing the effectiveness of the National Comprehensive Cancer Network genetic testing guidelines in identifying African American breast cancer patients with deleterious genetic mutations.
Ademuyiwa FO; Salyer P; Ma Y; Fisher S; Colditz G; Weilbaecher K; Bierut LJ
Breast Cancer Res Treat; 2019 Nov; 178(1):151-159. PubMed ID: 31325073
[TBL] [Abstract][Full Text] [Related]
35. Identification of germline genetic mutations in patients with pancreatic cancer.
Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
[TBL] [Abstract][Full Text] [Related]
36. Genetic testing in women with breast cancer: implications for treatment.
Paterson R; Phillips KA
Expert Rev Anticancer Ther; 2017 Nov; 17(11):991-1002. PubMed ID: 28853307
[TBL] [Abstract][Full Text] [Related]
37. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years.
Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
Engel C; Rhiem K; Hahnen E; Loibl S; Weber KE; Seiler S; Zachariae S; Hauke J; Wappenschmidt B; Waha A; Blümcke B; Kiechle M; Meindl A; Niederacher D; Bartram CR; Speiser D; Schlegelberger B; Arnold N; Wieacker P; Leinert E; Gehrig A; Briest S; Kast K; Riess O; Emons G; Weber BHF; Engel J; Schmutzler RK;
BMC Cancer; 2018 Mar; 18(1):265. PubMed ID: 29514593
[TBL] [Abstract][Full Text] [Related]
39. Germline mutation prevalence in individuals with pancreatic cancer and a history of previous malignancy.
Dudley B; Karloski E; Monzon FA; Singhi AD; Lincoln SE; Bahary N; Brand RE
Cancer; 2018 Apr; 124(8):1691-1700. PubMed ID: 29360161
[TBL] [Abstract][Full Text] [Related]
40. Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program.
Bychkovsky BL; Li T; Sotelo J; Tayob N; Mercado J; Gomy I; Chittenden A; Kane S; Stokes S; Hughes ME; Kim JS; Umeton R; Awad MM; Konstantinopoulos PA; Yurgelun MB; Wolpin BM; Taplin ME; Newmark RE; Johnson BE; Lindeman NI; MacConaill LE; Garber JE; Lin NU
Clin Cancer Res; 2022 Jun; 28(11):2349-2360. PubMed ID: 35363308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
